MAPT and Alzheimer disease: Our aim was to perform a detailed comparison of amyloid markers (Aβ38, Aβ40, Aβ42, sAβPPα, and sAβPPβ) and other markers studied in neurodegenerative disease (t-tau, p-tau, NFL, sTREM2, and neurogranin) in the CSF of patients with AD, CAA, and control (CS) participants in an exploratory hypothesis-generating study.